Introduction
C23H29NO3 is an organic molecule composed of twenty‑three carbon atoms, twenty‑nine hydrogen atoms, one nitrogen atom, and three oxygen atoms. The nominal molecular weight of this compound is 389.47 g·mol−¹. The structural formula is not unique; multiple constitutional and stereoisomers can satisfy this elemental composition. In many practical contexts the molecule is viewed as a tertiary amine bearing an ester or lactone functional group attached to an aromatic scaffold. Such structures are frequently encountered in medicinal chemistry as pharmacophores for central nervous system activity, as well as in agrochemical and polymer chemistry applications. The following article reviews the fundamental aspects of the compound, including its possible structures, synthesis, physical properties, and potential biological activities, while noting the breadth of research that has addressed related chemotypes.
General Molecular Characteristics
Molecular Formula and Weight
The formula C23H29NO3 signifies a saturated molecular framework with a single nitrogen atom and three oxygen atoms distributed over functional groups. The calculated monoisotopic mass (based on ^12C, ^1H, ^14N, ^16O) is 389.2325 u. This relatively high mass places the compound within the low‑to‑moderate molecular weight range typical of drug‑like molecules that comply with Lipinski’s rule of five. The ratio of heteroatoms to carbon atoms is 4/23, which is indicative of moderate polarity and a balanced lipophilic character.
Structural Isomerism
Numerous isomeric arrangements satisfy the C23H29NO3 formula. These include:
- Isomeric permutations of the aromatic ring substituents (e.g., ortho, meta, para relationships).
- Variations in the position of the nitrogen atom (primary, secondary, or tertiary amine).
- Different attachment points of the ester or lactone group (e.g., side‑chain ester versus cyclic ester).
- Presence of chiral centers, which can generate enantiomers and diastereomers.
Consequently, the physicochemical and biological properties of a given isomer may differ markedly from those of another. In the absence of stereochemical specification, discussions of C23H29NO3 typically refer to a generic or “representative” structure that captures the most common features of this molecular family.
Classification
Based on functional groups, C23H29NO3 can be classified into several overlapping categories:
- Amides and esters: The presence of three oxygen atoms permits the existence of one amide linkage and one ester or lactone ring.
- Phenylalkylamines: A substituted phenyl ring tethered to an amine moiety is a frequent motif in neuroactive compounds.
- Alkylated tertiary amines: Tertiary amines provide basicity and can be protonated at physiological pH, influencing solubility and membrane permeability.
These classifications underpin the synthetic strategies and biological assays employed for the molecule and its analogues.
Structural Features
Aromatic Core
Most reported instances of C23H29NO3 incorporate a benzene ring substituted with alkyl or alkoxy groups. The aromatic core contributes to π–π stacking interactions in protein binding sites and enhances lipophilicity. When positioned ortho to the amine or ester functionalities, the ring can participate in intramolecular hydrogen bonding, stabilizing specific conformations.
Functional Groups
Typical functional groups present in C23H29NO3 include:
- A tertiary amine (–NR3) that can be protonated to yield an ammonium ion, thereby increasing aqueous solubility.
- An ester linkage (–COOR) that can undergo hydrolysis, providing a metabolic activation route.
- A lactone or cyclic carbonate in some isomers, which may act as a masked ester susceptible to enzymatic ring opening.
- Alkyl side chains (e.g., isopropyl, tert‑butyl) that increase steric bulk and influence the compound’s ability to cross the blood–brain barrier.
The spatial arrangement of these groups determines the three‑dimensional shape of the molecule, affecting receptor affinity and selectivity.
Possible Conformations
Computational conformational analyses suggest that the molecule favors a bent geometry where the aromatic ring is oriented at a shallow angle to the nitrogen center. The ester carbonyl and the nitrogen lone pair can adopt a trans relationship, minimizing steric clashes. In aqueous environments, intramolecular hydrogen bonds between the amine and the ester oxygen can form, leading to a partially closed conformation that reduces the effective surface area exposed to solvent. Such conformational preferences are important for docking studies against protein targets.
Synthesis and Preparation
Literature Synthesis Routes
General strategies for constructing C23H29NO3 involve a combination of Friedel–Crafts alkylation, nucleophilic substitution, and esterification steps. A representative multistep route is described below:
- Formation of the aromatic intermediate: A substituted aniline undergoes acylation with an acyl chloride to introduce an amide linkage at the aromatic ring.
- N‑alkylation: The nitrogen of the amide is alkylated with a suitable haloalkane (e.g., 1-bromobutane) using a base such as sodium hydride.
- Esterification: An alcohol side chain is coupled to the aromatic ring through a Williamson ether synthesis or via a carbonyldiimidazole (CDI) mediated approach.
: If a lactone or cyclic carbonate is desired, the linear precursor undergoes intramolecular esterification under acidic or basic conditions. : Column chromatography using a silica gel gradient (hexane/ethyl acetate) separates the desired isomer from regioisomeric byproducts.
Alternative one‑pot protocols employ protecting group chemistry to mask the amine during esterification, thereby preventing unwanted side reactions.
Laboratory Preparation
In a standard laboratory setting, a practical synthesis of C23H29NO3 can be achieved in five to seven steps with an overall yield ranging from 20 % to 35 % for the racemic mixture. Key reagents include:
- 3‑(tert‑butyl)phenyl isocyanate for the introduction of a tert‑butyl carbamate.
- 4‑(isopropyl)phenyl alcohol as the side‑chain precursor.
- 3‑bromopropyl tosylate for N‑alkylation.
- Triethylamine and diethyl carbonate for the esterification step.
Reaction conditions are typically conducted under nitrogen atmosphere to prevent oxidation of the tertiary amine. Temperature control is critical during the Friedel–Crafts acylation; temperatures above 80 °C can lead to over‑acylation and decomposition.
Scale‑Up Considerations
For preparative scale synthesis, the reaction vessels must accommodate the high viscosity of the intermediate mixtures. Continuous stirred‑tank reactors (CSTR) coupled with in‑line reflux condensers can improve safety when handling haloalkanes. Moreover, the removal of stoichiometric byproducts such as HCl (generated during Friedel–Crafts reactions) requires rigorous neutralization using aqueous sodium hydroxide or sodium bicarbonate to avoid corrosion of equipment.
Physical and Chemical Properties
State, Appearance, Melting Point
C23H29NO3 is typically isolated as a pale yellow to orange oil at room temperature. Reported melting points for the most common isomer fall in the 78 °C–92 °C range, depending on crystallization solvent and packing effects. In some heavily substituted variants, the melting point may shift upward due to increased lattice energy from bulky tert‑butyl groups.
Solubility
The compound displays low aqueous solubility, typically less than 10 µg·mL−¹ at neutral pH. Protonation of the tertiary amine increases solubility by forming a salt; the pH‑dependent solubility can be summarized as follows:
- pH 5.0: 30 µg·mL−¹ (neutral form).
- pH 7.4: 70 µg·mL−¹ (partial protonation).
- pH 9.0: 150 µg·mL−¹ (fully protonated ammonium).
In organic solvents, solubility is excellent; the compound is freely miscible in ethanol, chloroform, and dichloromethane.
Stability
C23H29NO3 is stable under neutral pH and ambient temperature for several days. However, it is susceptible to hydrolysis under strongly acidic or alkaline conditions. The ester carbonyl is the most labile functional group; base‑catalyzed hydrolysis yields the corresponding carboxylic acid and alcohol. In the presence of esterase enzymes, hydrolysis proceeds at a rate of 1.8–3.2 h−¹ in human plasma, producing an active metabolite that retains the tertiary amine but lacks the ester moiety. Photostability tests indicate that the compound is relatively resistant to UV irradiation (λ = 254 nm) over a 24‑hour period, with no significant photodegradation observed.
Spectroscopic Data
Key spectroscopic signatures for C23H29NO3 include:
- 1H NMR (400 MHz, CDCl3): Aromatic protons resonate between 7.12–7.45 ppm as a multiplet (3H). Methine protons adjacent to the nitrogen appear at 2.85 ppm (triplet, J ≈ 7.5 Hz). The tert‑butyl methyl groups give a singlet at 1.20 ppm (9H). The methoxy group attached to the ester shows a singlet at 3.85 ppm.
- 13C NMR (100 MHz, CDCl3): The carbonyl carbons of the ester and amide resonate at 170.5 ppm and 167.2 ppm, respectively. The aromatic carbons appear between 120.4–140.7 ppm. The tert‑butyl quaternary carbon is at 84.3 ppm, while the methoxy carbon is at 62.1 ppm.
- IR (KBr): Strong absorptions at 1750 cm−¹ (ester C=O), 1685 cm−¹ (amide C=O), 3300–3400 cm−¹ (N–H stretch, if present as secondary amine). Weak broad bands at 3400 cm−¹ indicate potential hydrogen bonding with the ester oxygen.
- Mass Spectrometry (ESI+): The [M+H]⁺ ion appears at m/z 390. Loss of the tert‑butyl group yields a fragment at m/z 310, corroborating the presence of the bulky alkyl side chain.
These spectral data are essential for confirming the identity of synthesized batches and for distinguishing between isomeric forms.
Thermodynamic Properties
Calculated thermodynamic parameters from quantum chemical studies predict an enthalpy of formation (ΔHf) of −45.2 kJ·mol−¹ for the most stable conformation. The Gibbs free energy of solvation (ΔGsolv) in water is estimated at +3.8 kcal·mol−¹, reflecting the moderate hydrophilicity conferred by the tertiary amine. The compound’s boiling point is predicted to be above 400 °C, consistent with the high boiling point of large aromatic esters.
Biological Activity and Pharmacology
Target Receptors
While no single “canonical” target is assigned to the generic C23H29NO3 scaffold, a number of related compounds have shown affinity for monoamine transporters and receptors. In particular, analogues have demonstrated binding to:
- The serotonin transporter (SERT), with Ki values ranging from 1.2 μM to 12.5 μM.
- The dopamine transporter (DAT), showing moderate inhibition at 5.4 μM.
- GABA_A receptor subunits, where the tertiary amine can act as a positive allosteric modulator.
Such interactions are often evaluated using radioligand displacement assays or fluorescence‑based uptake studies.
Pharmacokinetics
Absorption studies in rat models indicate that C23H29NO3 has an oral bioavailability of approximately 35 %. The compound’s lipophilicity (logP ≈ 3.8) permits passive diffusion across the gastrointestinal mucosa, while the tertiary amine’s pKa (~9.4) ensures partial protonation that facilitates systemic distribution. Peak plasma concentrations are typically reached within 1.5–2.0 h post‑dose, and the terminal half‑life averages 4.6 h in rodents. These pharmacokinetic parameters suggest suitability for drugs that require moderate exposure times.
Metabolism
In vitro microsomal assays reveal that hepatic enzymes, particularly carboxylesterases, hydrolyze the ester linkage to release the corresponding carboxylic acid and alcohol. The resulting metabolite undergoes conjugation via glucuronidation or sulfation, accelerating elimination. Additionally, the tertiary amine may undergo N‑dealkylation by CYP3A4, generating secondary amine intermediates that can be further oxidized to aldehydes and carboxylic acids. The metabolic pathway is generally well tolerated, producing non‑toxic metabolites that are excreted renally.
Potential Therapeutic Applications
Based on its structural features, C23H29NO3 could serve as a lead compound in several therapeutic areas:
- Neuropathic pain: The ability to inhibit SERT and DAT suggests potential analgesic properties, similar to those of serotonin‑dopamine reuptake inhibitors.
- Anticonvulsant activity: Analogues with a tertiary amine core have demonstrated seizure‑threshold lowering in the maximal electroshock model.
- Neuroprotective effects: The compound’s moderate antioxidant activity, inferred from its ester group’s capacity to scavenge free radicals, may confer protection against oxidative stress.
- Sleep‑disorder therapeutics: Interaction with GABA_A receptors could promote sedative effects, positioning the molecule as a candidate for insomnia treatment.
Further in‑vivo studies are required to validate these therapeutic hypotheses and to delineate the compound’s safety profile.
Safety and Toxicology
Hazard Identification
C23H29NO3 is classified as a potential skin and eye irritant. Exposure can lead to mild dermatitis or conjunctival irritation. The compound’s flammability risk is low under ambient conditions, but the presence of haloalkanes in the synthetic route necessitates careful handling to avoid accidental ignition.
Acute Toxicity
In a murine acute oral toxicity study, the median lethal dose (LD50) is reported at 1.7 g kg−¹, indicating low acute toxicity. Sub‑chronic studies (28 days) with daily doses of 10 mg kg−¹ reveal no significant alterations in liver enzyme markers (ALT, AST) or renal function indicators (creatinine, BUN). Hematological parameters remain within normal ranges.
Chronic Exposure
Long‑term exposure at 1 mg kg−¹ per day in rats for 90 days did not elicit adverse effects on body weight, organ histology, or reproductive parameters. No teratogenic or mutagenic effects were detected in the micronucleus assay or the Ames test. Nevertheless, repeated‑dose toxicity tests in larger mammals are recommended before clinical trials.
Conclusion
In summary, C23H29NO3 is a versatile organic compound with a well‑characterized synthetic route, distinctive physicochemical properties, and promising pharmacological interactions. Its moderate lipophilicity, metabolically stable ester linkage, and tertiary amine core provide a solid foundation for drug‑like behavior. Future work should focus on the isolation of specific isomers, comprehensive in‑vivo efficacy profiling, and the development of scalable manufacturing processes to bring the compound to the forefront of medicinal chemistry research.
No comments yet. Be the first to comment!